News|Articles|October 2, 2023
New Market Opportunities for Pathogen-Targeted mAbs
Author(s)AGC Biologics
This research outlines recent changes in the monoclonal antibody market, the great potential for pathogen-focused mAb treatments and important industry factors impacting how to antibody products can navigate through clinical stages.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How Mitigation and Maintenance Protect Against Future Risk
2
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
3
FAQ: Milestones You May Have Missed in the 2025 Biopharma Pipeline
4
Roche Drives Industry Shift With Three-Year Lymphoma Survival Data
5
